Exosomes (extracellular vesicles) for hair loss

Key takeaways

• Nothing is approved. The FDA states there are no FDA-approved exosome products and that exosomes used to treat disease are regulated as drugs or biologics needing premarket approval (FDA safety notification, 2019; FDA consumer alert, 2020). Clinics selling exosome treatments are selling unapproved products. EU and UK status was not checked.
• Real harm has been reported for the product class. The 2019 FDA notice followed serious adverse events in patients treated with unapproved exosome products. A 2025 review found at least 10 serious adverse events across dermatology and aesthetics, but few side effects among the 125 hair-loss patients it located (Queen 2025).
• Human hair data are thin. The same review found only 9 relevant hair studies. A 2026 systematic review of 39 studies reported 8 to 20% density gains in early clinical work but flagged small samples, retrospective designs, no controls and inconsistent measures (Malih 2026).
• The headline meta-analysis is weak. A 2026 pooling of human aesthetic trials (13 on hair) found density +23.6% and thickness +18.0%, but heterogeneity and non-standard protocols limit it (Stack 2026). Percent change in uncontrolled studies cannot separate treatment from natural variation and placebo.
• Animal data are consistently positive. A review of 16 preclinical studies, mostly mouse models, found better coverage and more growing-phase follicles (Nareswari 2026). Mouse models predict human pattern loss poorly.
• Products are not standardized. Sources include human stem cells, platelets, plants and even milk, with unknown doses.
• Topical exosomes after microneedling are a leap. Microneedling did not improve growth-factor penetration in a histology study (Dhurat 2019), and a 20-patient uncontrolled series of radiofrequency microneedling plus exosomes reported higher density at 10 months with no comparison group (Koumprentziotis 2025).
• No published randomized trial shows exosomes beating minoxidil or finasteride.

What it is

Exosomes are nanoscale vesicles that carry proteins and RNA between cells. In hair products they are harvested from the culture fluid of cells such as mesenchymal stem cells, dermal papilla cells or platelets, or from plants. Many "exosome" products are really whole secretomes, which contain growth factors as well as vesicles, so it is unclear what does what. See stem cell and growth factor treatments.

How it might work

In animal and cell work the proposed effects are activation of Wnt/beta-catenin signalling in dermal papilla cells, suppression of TGF-beta signalling, and anti-inflammatory and blood-vessel effects around the follicle. None is proven in people.

What the studies show

• Behrangi 2026, systematic review of 20 studies (724 patients; extracellular vesicles in 3 studies, 89 patients): hair count +28%, higher in early pattern loss, mild side effects, cross-study comparison only (Behrangi 2026).
• Almost all human data are uncontrolled, small, short, and often from clinics that sell the product. Reviews repeat the same few primary studies, so counting reviews adds no evidence.
• Several small trials are registered, including exosomes versus PRP, but no results were found.

Side effects and safety

• Cell-free does not mean risk-free. Contaminated or poorly made unapproved products caused serious infections and injuries in the cluster behind the 2019 FDA notice.
• Spreading redness, heat, fever, pus or severe pain after injection need prompt medical care.
• There are no safety data in pregnancy or breastfeeding.
• Treatments abroad are not overseen by the FDA. US users can report problems to FDA MedWatch.
• If a clinic offers it, ask what the product is, who made it, and whether there is an FDA investigational-drug number or ethics-approved trial.

Bottom line

Exosomes are an investigational, unregulated add-on with promising lab data and weak human evidence. They sit well below minoxidil, finasteride and light therapy on the treatment ladder. Discuss with a doctor.